Unknown

Dataset Information

0

Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?


ABSTRACT: Despite many years of clinical experience with cefepime, data regarding the outcome of patients suffering from bloodstream infections (BSIs) due to Enterobacter cloacae (Ecl) are scarce. To address the gap in our knowledge, 57 Ecl responsible for 51 BSIs were analysed implementing phenotypic and molecular methods (microarrays, PCRs for bla and other genes, rep-PCR to analyse clonality). Only two E. cloacae (3.5%) were ESBL-producers, whereas 34 (59.6%) and 18 (31.6%) possessed inducible (Ind-Ecl) or derepressed (Der-Ecl) AmpC enzymes, respectively. All isolates were susceptible to imipenem, meropenem, gentamicin and ciprofloxacin. Der-Ecl were highly resistant to ceftazidime and piperacillin/tazobactam (both MIC???256 ?g/mL), whereas cefepime retained its activity (MIC?? of 3 ?g/mL). rep-PCR indicated that the isolates were sporadic, but Ecl collected from the same patients were indistinguishable. In particular, three BSIs initially due to Ind-Ecl evolved (under ceftriaxone or piperacillin/tazobactam treatment) into Der-Ecl because of mutations or a deletion in ampD or insertion of IS4321 in the promoter. These last two mechanisms have never been described in Ecl. Mortality was higher for BSIs due to Der-Ecl than Ind-Ecl (3.8% vs. 29.4%; P=0.028) and was associated with the Charlson co-morbidity index (P=0.046). Using the following directed treatments, patients with BSI showed a favourable treatment outcome: cefepime (16/18; 88.9%); carbapenems (12/13; 92.3%); ceftriaxone (4/7; 57.1%); piperacillin/tazobactam (5/7; 71.4%); and ciprofloxacin (6/6; 100%). Cefepime represents a safe therapeutic option and an alternative to carbapenems to treat BSIs due to Ecl when the prevalence of ESBL-producers is low.

SUBMITTER: Hilty M 

PROVIDER: S-EPMC4018813 | biostudies-other | 2013 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

Hilty Markus M   Sendi Parham P   Seiffert Salome N SN   Droz Sara S   Perreten Vincent V   Hujer Andrea M AM   Bonomo Robert A RA   Mühlemann Kathrin K   Endimiani Andrea A  

International journal of antimicrobial agents 20130110 3


Despite many years of clinical experience with cefepime, data regarding the outcome of patients suffering from bloodstream infections (BSIs) due to Enterobacter cloacae (Ecl) are scarce. To address the gap in our knowledge, 57 Ecl responsible for 51 BSIs were analysed implementing phenotypic and molecular methods (microarrays, PCRs for bla and other genes, rep-PCR to analyse clonality). Only two E. cloacae (3.5%) were ESBL-producers, whereas 34 (59.6%) and 18 (31.6%) possessed inducible (Ind-Ecl  ...[more]

Similar Datasets

| S-EPMC5731700 | biostudies-literature
| S-EPMC7744991 | biostudies-literature
| S-EPMC1221057 | biostudies-other
| S-EPMC8235818 | biostudies-literature
| S-EPMC9155248 | biostudies-literature
| S-EPMC3846452 | biostudies-literature
| S-EPMC6198125 | biostudies-literature
| S-EPMC3771936 | biostudies-literature
| S-EPMC6697253 | biostudies-literature
| S-EPMC2863489 | biostudies-literature